Literature DB >> 10549754

Intestinal obstruction after lung transplantation in children with cystic fibrosis.

R K Minkes1, J C Langer, M A Skinner, R P Foglia, A O'Hagan, A H Cohen, G B Mallory, C B Huddleston, E N Mendeloff.   

Abstract

BACKGROUND/
PURPOSE: Distal intestinal obstruction syndrome (DIOS) occurs in 15% of patients with cystic fibrosis (CF). The authors reviewed their experience to determine the incidence, risk factors, and natural history of adhesive intestinal obstruction and DIOS after lung transplantation.
METHODS: Eighty-three bilateral transplants were performed in 70 CF patients between January 1990 and September 1998. All were on pancreatic enzymes preoperatively, and none had preoperative bowel preparation. Fifty-six patients (80%) had prior gastrostomy (n = 54) or jejunostomy (n = 2). Eighteen patients (25.7%) had a previous laparotomy for meconium ileus (n = 8), fundoplication (n = 4), liver transplant (n = 1), jejunal atresia (n = 1), Janeway gastrostomy takedown (n = 1), pyloromyotomy (n = 1), free air (n = 1), or appendectomy (n = 1).
RESULTS: After lung transplantation, 7 patients (10%) required laparotomy for bowel obstruction (6 during the same hospitalization, and 1 during a subsequent hospitalization). The causes of obstruction were adhesions only (n = 1), DIOS only (n = 2), and a combination of DIOS and adhesions (n = 4). Adhesiolysis was performed in the 5 patients with adhesions, and a small bowel resection was also performed in 1 patient. DIOS was treated by milking secretions distally without an enterotomy (n = 3) with an enterotomy and primary closure (n = 1) or with an end ileostomy and mucus fistula (n = 2). Five had recurrent DIOS early postoperatively. One resolved with intestinal lavage, 2 were treated successfully with hypaque disimpaction, and 2 underwent reoperation; 1 required an ileostomy. The most important risk factor for posttransplant obstruction was a previous major abdominal operation. Obstruction occurred in 7 of 18 (39%) who had undergone a prior laparotomy versus 0 of 52 who had not (P < .001, chi2).
CONCLUSIONS: (1) The incidence of intestinal obstruction is high after lung transplantation in children with CF. (2) Previous laparotomy is a significant risk factor. (3) Recurrent obstruction after surgery for this condition is common. (4) Preventive measures such as pretransplant bowel preparation and early postoperative bowel lavage may be beneficial in these patients.

Entities:  

Mesh:

Year:  1999        PMID: 10549754     DOI: 10.1016/s0022-3468(99)90110-0

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  6 in total

1.  Distal intestinal obstruction syndrome in the early postoperative period after lung transplantation in a patient with cystic fibrosis: morphological findings on computed tomography.

Authors:  K Nassenstein; B Schweiger; M Kamler; J Stattaus; T Lauenstein; J Barkhausen
Journal:  Gut       Date:  2005-11       Impact factor: 23.059

2.  Intraoperative intraluminal injection of N-acetylcysteine allowing treatment of distal intestinal obstruction syndrome without the need for enterotomy.

Authors:  Nicholas Js Chilvers; James Wheeler
Journal:  BMJ Case Rep       Date:  2018-05-16

Review 3.  The pulmonary physician in critical care. Illustrative case 1: cystic fibrosis.

Authors:  S R Thomas
Journal:  Thorax       Date:  2003-04       Impact factor: 9.139

4.  Treatment of Gastrointestinal Problems in Cystic Fibrosis.

Authors:  Maria R. Mascarenhas
Journal:  Curr Treat Options Gastroenterol       Date:  2003-10

5.  Distal intestinal obstruction syndrome (DIOS) in patients with cystic fibrosis after lung transplantation.

Authors:  Jonathan R Morton; Nabila Ansari; Allan R Glanville; Alan P Meagher; Reginald V N Lord
Journal:  J Gastrointest Surg       Date:  2009-05-22       Impact factor: 3.452

6.  Distal intestinal obstruction syndrome: a diagnostic and therapeutic challenge in cystic fibrosis.

Authors:  Natascha S Sandy; Lilian H P Massabki; Aline C Gonçalves; Antonio F Ribeiro; Jose D Ribeiro; Maria de Fátima C P Servidoni; Elizete A Lomazi
Journal:  J Pediatr (Rio J)       Date:  2019-10-22       Impact factor: 2.990

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.